ABBV: Immunology and neuroscience drive growth, with pipeline innovation and strategic deals fueling expansion
Strong growth in immunology and neuroscience has offset major revenue erosion, with a robust pipeline spanning immunology, oncology, CNS, and obesity. Strategic acquisitions like Apogee and innovative combination therapies support long-term expansion, while policy advocacy and AI adoption enhance c…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.